Immunocore Holdings PLC IMCR.OQ IMCR.O is expected to show a rise in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025
The Abingdon Oxfordshire-based company is expected to report a 28.8% increase in revenue to $103.357 million from $80.25 million a year ago, according to the mean estimate from 15 analysts, based on LSEG data.
LSEG's mean analyst estimate for Immunocore Holdings PLC is for a loss of 27 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Immunocore Holdings PLC is $67.50, about 52.3% above its last closing price of $32.19
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.17 | -0.20 | -0.20 | Met | -1.7 |
Mar. 31 2025 | -0.37 | -0.39 | 0.10 | Beat | 125.7 |
Dec. 31 2024 | -0.29 | -0.26 | -0.47 | Missed | -83 |
Sep. 30 2024 | -0.35 | -0.35 | 0.17 | Beat | 148.4 |
Jun. 30 2024 | -0.55 | -0.48 | -0.23 | Beat | 51.7 |
Mar. 31 2024 | -0.38 | -0.36 | -0.49 | Missed | -35.4 |
Dec. 31 2023 | -0.28 | -0.28 | -0.40 | Missed | -47 |
Sep. 30 2023 | -0.35 | -0.35 | 0.05 | Beat | 113.8 |
This summary was machine generated October 31 at 11:27 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)